Foreign Body Granulomas after All Injectable Dermal Fillers: Part 2. Treatment Options

Author
Lemperle, Gottfried

Publication Date
2015-04-05

Peer reviewed
Foreign Body Granulomas after All Injectable Dermal Fillers: Part 2. Treatment Options

Gottfried Lemperle, M.D., Ph.D.
Nelly Gauthier-Hazan, M.D.
San Diego, Calif.; and Paris, France

Summary: Foreign body granulomas occur at certain rates with all injectable dermal fillers. They have to be distinguished from early implant nodules, which usually appear 2 to 4 weeks after injection. In general, foreign body granulomas appear after a latent period of several months at all injected sites at the same time. If diagnosed early and treated correctly, they can be diminished within a few weeks. The treatment of choice of this hyperactive granulation tissue is the intralesional injection of corticosteroid crystals (triamcinolone, betamethasone, or prednisolone), which may be repeated in 4-week cycles until the right dose is found. To lower the risk of skin atrophy, corticosteroids can be combined with antimitotic drugs such as 5-fluorouracil and pulsed lasers. Because foreign body granulomas grow fingerlike into the surrounding tissue, surgical excision should be the last option. Surgery or drainage is indicated to treat normal lumps and cystic foreign body granulomas with little tissue ingrowth. In most patients, a foreign body granuloma is a single event during a lifetime, often triggered by a systemic bacterial infection. (Plast. Reconstr. Surg. 123: 1, 2009.)

An increasing number of various injectable dermal filler substances are being used for the treatment of wrinkles, acne scars, and facial lipodystrophy. They have been developed because injection of earlier substances, such as paraffin and silicone oil, was followed by a high incidence of late granuloma formation. In addition, the effects of collagen and hyaluronic acids, considered the accepted standard, do not last longer than 6 months before they are resorbed. Paraffin oil used some 100 years ago led to paraffinomas, and injection of low-viscosity silicone oil of 350 centistoke caused late siliconomas in selected patients in the 1970s. In the early 1980s, bovine collagen (Zyderm and its cross-linked form Zyplast) appeared to be safe but caused granulomas in selected patients as well.

In the early 1990s, the first particulate injectables, Bioplastique and Arteplast, were introduced in Europe. These substances, however, caused foreign body granulomas at unacceptably high rates—the first because of the irregular shape of its silicone particles, the latter due to a high amount of small phagocytosable polymethylmethacrylate particles among the smooth and even microspheres. Unfortunately, polymethylmethacrylate products with a high percentage of impurities are widely injected in Brazil. Today, ArteFill is a third-generation polymethylmethacrylate–based filler that has substantial improvements, including microspheres, which have enhanced uniformity and consistency, compared with the second-generation polymethylmethacrylate–based product, Artecoll.

At the end of the 1990s, Dermalive, a suspension of slowly resorbable acrylic (hydroxyethylmethacrylate) particles from ground intraocular lenses, and New-Fill/Sculptra, faster resorbed microspheres from polylactic acid, entered the European market. A few years later, the first reports of late granuloma formation appeared. Restylane, a hyaluronic acid derived from Streptococcus equi, was introduced in 1998, and some patients reacted with the formation of late granulomas.

Radiesse (formerly Radiance), consisting of microspheres composed of calcium-hydroxylapa-

Disclosure: Gottfried Lemperle, M.D., Ph.D., is not affiliated with nor an agent nor a representative of Artes Medical, Inc., which is the manufacturer of ArteFill. Dr. Lemperle is a shareholder of Artes Medical, Inc. Nelly Gauthier-Hazan, M.D., has no financial interest in any of the products mentioned in this article.
tite and suspended in methylcellulose, is a filler substance introduced in the United States in 2002 for off-label use in wrinkles and lip augmentation; it received U.S. Food and Drug Administration approval for the treatment of nasolabial folds and human immunodeficiency virus–associated lipoatrophy in 2006. So far, Radiesse appears to cause the lowest rate of foreign body granulomas among all filler substances.

Finally, polyacrylamide gel was the Russian answer to the American silicone gel for soft-tissue augmentation in the 1980s and 1990s. Today, different formulations of polyacrylamide are produced by at least five manufacturers since Interfall Ltd., in Kiev, Ukraine, lost its European patent protection of Formacryl and Interfall in 1995. Aquamid and Bio-Alcamid are the products most widely used in Europe today, besides Interfall and Amazing Gel in China.

Recently, resorbable microspheres from dextran suspended in hyaluronic acid were introduced in Europe as dermal fillers under the trade names Reviderm intra and Matridex. They are used as urinary bulking agents to treat incontinence. Matridex is currently in clinical trials in the United States. Both stimulate heavy granulomatous response but have not been used long enough to provide sufficient insight into potential late complications. Dextran granuloma, however, has been described in rats and has caused urinary obstruction in humans.

FOREIGN BODY GRANULOMAS AFTER DIFFERENT FILLERS

There are three different clinical and histological types of foreign body granulomas. Biological substances, such as collagen and hyaluronic acids, may cause cystic granulomas, which may eventually result in a sterile abscess. They occur between 2 and 12 months after injection and last without treatment for 2 to 12 months before spontaneous absorption. Permanent injectable fluids, such as silicone and polyacrylamide, may cause edematous granulomas, with swelling and surrounding inflammation. Particulate injectables, such as Artecoll, Dermalive, and Sculptra, may cause sclerosing granulomas, which occur between 6 and 24 months after injection and will remain for several years if not treated. Of course, there is a continuum among the three types, and certain granulomas sometimes are a blend of two types.

Silicone

The spontaneous disappearance of silicone foreign body granulomas after a 3-year follow-up period has been observed. If the reaction is limited to firm nodules, corticosteroid injections into the cellular tissue surrounding the silicone implant should be the first treatment choice. Complete remission of silicone foreign body granulomas in two patients has been obtained with a systemic antibiotic (minocycline 100 mg) given twice a day, orally. “Liposuction” or puncturing and squeezing of larger silicone fluid implants can be tried, but surgical excisions should be avoided, as removal will seldom be complete due to the silicone’s fingerlike insinuation into the tissue. Total excision and flap coverage should be reserved as a last option in patients with extreme infiltration and inflammation of the skin on the nose or breast.

Bovine Collagen

Moscona et al. described a woman who developed severe sclerosing foreign body granulomas at all injection sites 2.5 years after implantation of Zyderm I collagen into her nasolabial folds, glabellar frown lines, and a few areas around the lips. High doses of oral prednisolone, up to 60 mg/day, resulted in a marked diminution of the swelling, but the foreign body granulomas rapidly recurred when the treatment was stopped. Further treatment with intralesional triamcinolone injections resulted in almost complete regression for a period of 4 to 6 weeks, after which the foreign body granulomas recurred. In the latter case, no doses were reported, but we assume that they did not exceed 40 mg per session. Slight improvement was noted over the following years with low daily doses of 5 and 10 mg of Dexamethasone.

Hyaluronic Acids

Late foreign body granulomas developed 2 to 11 months after injection of hyaluronic acids and lasted 2 to 10 months without treatment. Some were treated with intralesional triamcinolone, but most resolved without treatment within 1 year. We are aware of four sclerosing but rather soft Restylane granulomas with late onsets of up to 3.5 years after injection. Systemic or local antibiotics are ineffective, but puncturing and squeezing out the whitish gel will speed up their resolution. Surgical excision of this cellular reaction should certainly be the last solution.

Polymethyl-Methacrylate Microspheres

Because of the extensive fibrous network associated with polymethyl-methacrylate–related granulomas, intralesional corticosteroid injec-
tions are considered the best treatment.\textsuperscript{11} We saw an Arteplast granuloma develop as late as 10 years after injection; it responded well to high doses of local steroids and pulsed light therapy (Fig. 1). A few cases of resistance to this treatment, probably due to insufficient initial doses of steroids, have been reported. If widened capillaries remain, they can be treated using different types of light therapy. Excision should be the very last option (as with all granulomas) because of the insinuations of the foreign body granulomas into the surrounding tissue. After sieving and washing, the second-generation Artecoll caused a significantly lower number of foreign body granulomas compared with polymethyl-methacrylate products with a high content of small particles.\textsuperscript{1,13}

### Polylactic Acid Microspheres

Polylactic acid beads suspended in cellulose (New-Fill/Sculptra) was first used successfully in human immunodeficiency virus patients with facial lipodystrophy in France and England. In the beginning, it was diluted 1:3 with saline and caused a high percentage of palpable but not visible small subcutaneous nodules. The presently recommended suspension of one part powder with five parts of saline has significantly reduced the occurrence of lumps. They still become visible after injections into lower eyelids,\textsuperscript{38} when New-Fill or Sculptra suspensions are not implanted strictly epiperiosteally.\textsuperscript{39}

### Poly-Hydroxyethyl-Methacrylate Particles

A relative high rate of foreign body granulomas occur 4 months to 3 years after Dermalive\textsuperscript{40,41} implantation; the granulomas are best treated with triamcinolone injections (Fig. 2). Because hypersensitivity reactions and foreign body granulomas occur much less frequently in subcutaneous tissue, DermaDeep will cause less visible side effects, as does Bioplastique,\textsuperscript{8,10} when it is implanted epiperiosteally compared with subdermally. We saw a 63-year-old patient who suddenly developed a generalized granulomatosis annulare of about 60 red flat infiltrates up to 3 cm in diameter on the face, trunk, and extremities 1 year after peri-oral Dermalive injections. They did not react to local triamcinolone and 5-fluorouracil injections but to 7 mg of betamethasone (Diprosone) administered intralesionally a total of five times in one session. No rheumatism was observed, but some recurrences are currently being treated with Allopurinol\textsuperscript{40} and Diprosone. Another patient developed localized sclerosing edematous foreign body granulomas at all injection sites in the face and is still being treated with systemic steroids and surgery.

Obviously, granuloma formation is a single event triggered by an infectious, traumatic, or pharmacological stimulus.\textsuperscript{1} If it is treated early and with sufficiently high doses of corticosteroids or other agents that inhibit cellular activities,\textsuperscript{45} it does not recur.

### THE TREATMENT OF GRANULOMAS AND IMPLANT NODULES

#### Intralesimal Injections of Steroids

Foreign body granulomas consist mainly of a cellular multiplication with little therapeutic effect. Even for the resorbable fillers, most particulate or artificial material cannot be broken down...
faster by granuloma formation. A granuloma is more of a frustrated reaction, like the fusion of macrophages into giant cells, which are in no way more effective. The goal in the treatment of foreign body granulomas must be to stop the invasion of cells and increased secretion of interstitial substances without leaving a scar. Triamcinolone decreases both cellular proliferation and invasion and collagen production by dermal fibroblasts. Alteration of cytokine levels (e.g., an increased production of transforming growth factor beta-1 by dermal fibroblasts) may mediate these effects. In the rat model, dexamethasone drastically interfered with both the synthesis and the degradation of type I and III collagen and significantly decreased fibril collagen content. This explains the impaired wound healing and occasional skin atrophy caused by corticosteroids.

Therefore, the treatment of choice is the strictly intralesional injection of triamcinolone (Kenalog, Volon A) at 40 mg or betamethasone (Diprosone) or methylprednisolone (Depo-Medrol; Pharmacia & Upjohn, Bridgewater, N.J.) as soon as possible (Table 1). The latter two drugs can be used undiluted, but triamcinolone should be diluted 1:1 with lidocaine. Intralesional triamcinolone is approved by the Food and Drug Administration for the treatment of keloids, hypertrophic scars, and granuloma annulare, but it is not approved to treat foreign body granulomas even though it has been the treatment of choice since the early 1960s. The initial dose has to be sufficiently high (Fig. 2), although this risks skin depressions, to avoid frequent recurrences. The fact that foreign body granulomas treated with sufficiently high doses of corticosteroids seldom recur cannot be explained at this time. Therefore, radical surgical removal of foreign body granulomas is never indicated in the first place.

On the other hand, nodules and foreign body granulomas with little capsule formation and little tissue ingrowth, such as cystic foreign body granulomas injection of after collagen or hyaluronic acid or packed nodules of Radiesse, Dermalive, silicone, and polyacrylamides will not react to intralesionally injected corticosteroids or antimitotic drugs at all. Surgical removal of cysts and nodules, especially from the lips, is probably the method of choice for these cases. Lambros reports an anecdotal case of a woman with lumps in her tear troughs 1 week after injections of a hyaluronic acid filler; the lumps disappeared immediately after intralesional injections of hyaluronidase. This possibility of depolymerization of hyaluronic acid should be kept in mind for the treatment of early nodules but not foreign body granulomas.

All implant nodules with a high percentage of connective tissue content (Articoll, Bioplastique, New-Fill/Sculptra, Reviderm intra, MatriDex) and genuine foreign body granulomas of these prod-

**Table 1. Proven Treatments of Granulomas**

<table>
<thead>
<tr>
<th>Proven Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triamcinolone (Kenalog, Volon-A) 20–40 mg intralesionally</td>
</tr>
<tr>
<td>Triamcinolone (1 mg/ml) + 5-fluorouracil (50 mg/ml) intralesionally</td>
</tr>
<tr>
<td>Prednisolone (Depo-Medrol) 20–40 mg undiluted (N.G.-H.)</td>
</tr>
<tr>
<td>Betamethasone (Diprosone) 5–7 mg intralesionally</td>
</tr>
<tr>
<td>1:3 Betamethasone (Diprosone) 3.5 mg + 1:3 5-fluorouracil (1.6 ml) + 1:3 lidocaine intralesionally</td>
</tr>
</tbody>
</table>

**Fig. 2.** (Above) Sclerosing granuloma (Dermalive) 2 years after injection and 3 months after onset. (Below) Total resolution after treatment with intralesional methylprednisolone at 80 mg. At recurrence 9 months later, methylprednisolone at 80 mg and 30 mg, as well as betamethasone at 5 mg and three sessions of intense pulsed light, was applied. There has been no recurrence in the past 3 years.
ucts react well to intralesional crystalline corticosteroids. The same volume reduction can be expected if nodules are accidentally dislocated by muscle movement, if too much implant material is injected, or if hypertrophic scarring occurs because of an injection being too superficial. Local steroids inhibit fibroblast activity and collagen deposition, macrophage activity and giant cell formation, swelling, itching, and pain. Because particulate implants consist of approximately 80 percent of the patient's own granulation or fibrous tissue, it can be diminished as with a hypertrophic scar to half of its volume by a variety of growth depressants and antimitotic agents.

A 1:1 mixture of lidocaine and triamcinolone at 40 mg (Kenalog or Volan-O), methylprednisolone (Depo-Medrol) at up to 40 mg (and even 80 mg (Fig. 1)), or betamethasone (Diprosone) at up to 5 mg can be injected safely through a 1-ml insulin syringe with Luer lock and a 30-gauge needle. It must be injected strictly into the nodule held between two fingers while the needle is guided back and forth; strong resistance to the needle should be felt. Because corticosteroids injected into the surrounding tissue may cause temporary skin atrophy, one should stop injecting as soon as the resistance of the nodule lessens, and start again from a different angle. Because of their high cellular content, granulomas are much easier to inject than nodules.

A combination of triamcinolone injections with cryotherapy has been advocated. Also, a combination of intralesional steroid with pulsed light treatment (Flash-lamp) (Figs. 1 and 2, below) of the area has proven effective, especially on the face. Cryotherapy has been advocated. Also, a combination of 3:1 lidocaine (1.5 IU/ml) with triamcinolone at up to 5 mg can be injected safely through a 1-ml insulin syringe with Luer lock and a 30-gauge needle. It must be injected strictly into the nodule held between two fingers while the needle is guided back and forth; strong resistance to the needle should be felt. Because corticosteroids injected into the surrounding tissue may cause temporary skin atrophy, one should stop injecting as soon as the resistance of the nodule lessens, and start again from a different angle. Because of their high cellular content, granulomas are much easier to inject than nodules.

Another combination of triamcinolone with interferon-α2b has been applied successfully in keloids by injecting triamcinolone every 2 weeks and interferon twice a week. This combination may be worth considering for patients with foreign body granulomas who have a history of failed corticosteroid injections.

Many physicians are reluctant to use local corticosteroids. These agents can cause skin atrophy in 20 to 30 percent of patients, independent of dose; the patient should be fully aware of this side effect. If one is not under time pressure, one could offer a local steroid test by injecting undiluted crystals as a little bleb in the subcutaneous fat of the neck below the hairline and waiting 8 weeks. One can also find the right dose by increasing it each time, preventing possible atrophy with a lower starting dose.

If there is no improvement after 2 to 4 weeks, the dose should be doubled. In some African and Asian children with huge keloids, we have injected up to 160 mg of triamcinolone intralesionally every 4 weeks over a period of 6 months until the lesion remained flat. We cannot recall any visible systemic effect in these children. It is probable betamethasone (Fig. 4) and methylprednisolone cause less skin atrophy than triamcinolone. Should skin atrophy occur, temporary filling with collagen or hyaluronic acid will level the indentation until natural recovery occurs within 3 to 12 months.

### Antimitotic Agents

The risk of cortisone skin atrophy might be reduced by the injection of antimitotic agents such as 5-fluorouracil, which is mixed with 1:3 Diprosone and 1:3 lidocaine 2% without epinephrine and injected intralesionally every 3 weeks, if necessary. The anti-inflammatory action of this mixture is astonishing: the painful tension and redness, which are sometimes associated with foreign body granulomas, subside immediately, growth stops, and the foreign body granulomas diminish within a few weeks. Betamethasone (Diprosone) is supposed to have a less damaging
effect on the surrounding tissue than triamcinolone and methylprednisolone.

The pure mixture of intralesional 5-fluorouracil (here 1.6 ml of a 500 mg/10 ml 5-fluorouracil solution) with 0.4 ml of betamethasone (7 mg/ml) decreases cell proliferation and invasion and releases collagenase activity within the granuloma. From their 9-year experience in treating hypertrophic scars, Fitzpatrick and Manuskiatti and Narins et al. recommend pure 5-fluorouracil (50 mg/cc) intralesionally or mixed with 1 mg/cc of Kenalog. Frequent initial injections administered one to three times per week were more efficacious than higher single doses. Besides inhibiting tumor growth, cytostatics also inhibit collagen synthesis and are effective in the treatment of keloids and hypertrophic scars. Bleomycin (1.5 IU/ml) has been injected intralesionally into keloids and hypertrophic scars and should work successfully in granulomas as well.

**Systemic Corticosteroids and Alternative Drugs**

In general, the resolution of granulomas and nodules by corticosteroids is a matter of dosage, compliance, guidance, and patience on both sides. Some lumps will be reduced satisfactorily after one shot (Fig. 3), and some need three to six injections over a period of 3 to 6 months (Fig. 4). Some may recur and need touch-up treatment with triamcinolone, some react preferably to betamethasone, and some may react to cytostatics alone. Systemic doses must be much higher than those used for local intralesional injection. A starting dose of 30 mg/day of prednisone had to be increased to 60 mg/day because of recurrence, and ibuprofen (1800 mg/day) was added for a successful treatment of 16 weeks. The patient remained asymptomatic at 2 years.
The antibiotic minocycline (100 mg twice daily) has been given systemically in diffuse silicone granulomas developing 8 and 5 years after injection. Prednisone treatment (1 mg/kg/day) had to be interrupted because of glucose intolerance. The authors relate its antigranulomatous properties to minocycline’s immune-modulating effect.

Reisberger et al. successfully treated a patient with Arteplast granulomas on the forehead with Allopurinol, an effective treatment for gout using 200 to 600 mg/day administered over a period of 24 weeks. The same effect could be obtained with colchicine and the retinoic acid isotretinoin (Accutane) and doxycycline.

Baumann and Kerdel successfully treated a patient with acute allergy to bovine collagen, who did not respond to oral and intramuscular steroids (prednisone at 40 mg over 3 days and additional 9 mg of Celestone intramuscularly), with cyclosporine (5 mg/kg/day = 175 mg pro twice daily). After 2 weeks, the reaction subsided. They also reported the successful treatment of a silicone foreign body granuloma of the lips with an immunomodulatory cream [imiquimod 5% (Aladara)] that is known to increase levels of interferon alpha. The release of cytokines, interferon, and tumor necrosis factor enhances antiproliferative properties and collagenase activity. The swollen lips improved dramatically after 2 weeks of topical treatment, and the twice-daily treatment could be stopped after 2 months of consecutive treatment.

Tacrolimus cream appears to be effective in treating granuloma annulare and solved the local symptoms of collagen allergy as well. Tacrolimus has a mechanism of action similar to that of cyclosporine: both inhibit T-cell activation, interferon, and the release of preformed mediators from mast cells and basophils.

Many patients, however, have experienced spontaneous improvement of their condition over time. Therefore, at least five patients should be treated with every new regimen before it can be recommended as an effective therapy of foreign body granulomas (Table 2).

**Laser Treatment of Telangiectasia**

Small noninflammatory granulomas have responded well to long-pulsed 532-nm lasers; larger inflammatory granulomas have shown some favorable responses to 1064-nm long-pulsed lasers. The bluish discoloration of some superficial sclerosing foreign body granulomas can be treated effectively by “flashing” with intense pulsed light in the same range (e.g., that of the targeting blood vessels) (Fig. 2). Four to five sessions not only block the neovascularization but appear to soften and decrease the volume of the underlying granuloma, probably by reducing its blood supply from above.

**No Surgical Excisions!**

Plastic surgeons tend to excise all lumps in places where they do not belong, whereas dermatologists, in general, try corticoid creams first. Both approaches are contraindicated in foreign body granulomas. Surgical excision of genuine granulomas will be incomplete because of their invasiveness and nonconfined borders with the surrounding tissue. Attempts to excise and extricate injected fluids such as silicone and acrylamide meet with dire results, causing fistulas, abscesses, continuous granulation tissue, and marked deformities, even if bacteriological cultures have proven negative. In addition, surgical excisions may leave scars in the face but not in the lips.

Some hard nodules in the soft tissue of the lips, however, may not react well and are disturbing to the patient. In these rare cases, surgical excision, always approached from the inside, will be the best treatment. In general, foreign body nodules can be removed in the manner of a small atheroma by blunt dissection, due to the presence of the fibrous capsule that develops after 3 to 6 months. If excision of displaced material becomes necessary in a facial fold, the scar can be well hidden in the fold, especially in elderly patients.

Surgery is absolutely contraindicated in the vermilion because of the implant’s proximity to the thin dermis of the vermilion border (“white roll”) and because of the possibility of uncontrolled scarring. If indentations or irregularities occur after surgery, they can be treated with superficial touch-ups of absorbable filler substances, such as collagen or hyaluronic acid, as well as with additional corticoid injections, if necessary.

Similarly, radical excision of implants or foreign body granulomas from enlarged lips should be avoided under all circumstances. We are aware of three cases of radical excision of implants after lip augmentation, one in Frankfurt in 1998, one in Stockholm in 2004, and one in Regensburg in 2005. In all three patients, the orbicularis oris muscle was compressed by the implants for years and did not recover at all, as is well known from fat and breast tissue after removal of a silicone implant. Instead, stepwise horizontal volume reduction with the help of a 16-gauge trocar and simultaneous steroid injections should be tried.
Whether injections of hyaluronidase55,76 work in Restylane foreign body granulomas is doubtful, but it is possible in early stages in combination with triamcinolone. The effect of injected collagenolytic agents (collagenase) into collagen nodules has not been reported yet.

CONCLUSIONS

Foreign body granulomas can be treated effectively with intralesional injections of corticosteroids. Prerequisite is a correct diagnosis, which takes into account whether there is enough cellular ingrowth to react to the inhibiting effect of corticosteroids and antimitotic drugs. In general, early nodules are compressed implants and do not react to invasion or proliferation-inhibiting medication. The same is true for foreign body granulomas after the injection of gels such as silicone and polyacrylamide, and for cystic foreign body granulomas after injection of collagen or hyaluronic acids; these granulomas have to be drained first. In sclerosing foreign body granulomas, however, determining the right intralesional dose may be difficult and may delay the final outcome. Systemic steroids are indicated in all edematous foreign body granulomas in which intralesional steroids are difficult to apply. Otherwise, systemic steroids take effect much too late and require an unnecessarily long treatment period, with all the accompanying psychological problems. Creams, in general, are absorbed too superficially and do not reach the subdermally located foreign body granulomas.

REFERENCES

Volume 123, Number 6 • Treatment of Dermal Filler Granulomas


75. El-Shafey El-SI. Complications from repeated injection or puncture of polyacrylamide gel implant sites: Case reports. *Aesthetic Plast Surg.* 2008;32:162.

AUTHOR PLEASE ANSWER ALL QUERIES

AQ1: AUTHOR—Please confirm that ref. 2 is the reference number wanted for Interfall.

AQ2: AUTHOR—Is ref. 1 meant here, or is it the beginning of a list of three items?

AQ3: AUTHOR—Please supply the name and city/state location of the maker of Dexacort, or use the generic drug name.

AQ4: AUTHOR—Please supply the name and city/state location of the maker of Diprosone, or delete the brand name and use just the generic drug name. Please do the same for Allopurinol in the next sentence.

AQ5: AUTHOR—Please supply the name and city/state locations of the makers of Kenalog and Volon A, or delete the brand names and use just the generic drug names.

AQ6: AUTHOR—Please supply the name and city/state location of the maker of Celestone.

AQ7: AUTHOR—Please expand “pro” in “175 mg pro twice daily.”

AQ8: AUTHOR—Please supply the name and city/state location of the maker of Aldara.

AQ9: AUTHOR—Is “16-gauge trocar” meant for “16G trocar”?

AQ10: AUTHOR—Ref. 1: Please supply folio (cm29 in this issue).

AQ11: AUTHOR—Please complete ref. 12.

AQ12: AUTHOR—Please supply third author’s initial in ref. 34.